Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?

The market didn't like what this stock had to say this morning…

| More on:
Shot of a senior scientist looking stressed out while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After a strong start to the morning's trade, things don't look so upbeat for the S&P/ASX 200 Index (ASX: XJO) this afternoon. At the time of writing, the ASX 200 has given up most of its early lead today, and is sitting pretty much flat at 8,226 points. But let's talk about one ASX 200 healthcare stock that is plunging in value.

That ASX 200 healthcare stock is none other than Neuren Pharmaceuticals Ltd (ASX: NEU).

Yesterday, Neuren shares closed at a flat $12 each. This morning, those same shares opened at $12.03 but quickly started dropping. At the time of writing, the ASX 200 healthcare stock has lost a horrid 8.83% and is down to just $10.94 a share. That's after going as low as $10.90 this afternoon.

So what on earth is going on here that has seen Neuren lose close to 10% of its value in just a single trading day?

Well, it appears that this steep sell-off is a consequence of an ASX announcement Neuren made to investors this morning just before market open.

Neuren shares plunge amid big Europe news

This announcement revealed that Neuren's partner, Acadia Pharmaceuticals, has submitted a marketing authorization application to the European Medicines Agency for its trofinetide treatment. Trofinetide is a therapeutic treatment for Rett syndrome in adults and pediatric patients two years and older.

Acadia Pharmaceuticals reportedly expects approval for trofinetide to occur in the first quarter of 2026. If it does indeed gain approval from the relevant agencies, it will be the "first and only approved therapy for Rett syndrome in the European Union".

Trofinetide is already an approved treatment for Rett syndrome in the United States and Canada under the 'Daybue' trademark.

If approved, Acadia will sell trofinetide in Europe under license from Neuren. Upon the first commercial sale of the treatment in Europe, Neuren is contracted to receive a US$35 million payment from Acadia. That's in addition to ongoing royalty payments.

Why has this ASX 200 healthcare stock taken a dive?

It's not entirely clear why investors have reacted so poorly to this news out of Neuren today. The rollout of trofinetide in Europe has been anticipated for some time.

Perhaps investors were expecting a quicker European rollout or an announcement regarding other planned rollouts in Japan and other countries.

Regardless, it's a rough day for this ASX 200 healthcare stock. It's also some fresh salt in the wounds of Neuren's investors.

After today's share price plunge, this ASX 200 healthcare stock is down a painful 53.6% over the past 12 months. Investors will no doubt hope for a turnaround over the rest of 2025.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »